AlloSource Announces Milestone In Production Of Bioengineered Blood Vessels For Humacyte’s Vascular Access Phase III Clinical Trial
Centennial, Colo. – September 12, 2017 — AlloSource, one of the nation’s largest providers of cartilage, bone, skin, soft-tissue and cellular allografts for use in surgical procedures to advance patient healing, today announced a major milestone in its partnership with Humacyte. AlloSource…
September 12, 2017Press ReleasesFood and Drug Administration (FDA),HUMACYL®,hemodialysis,Humacyte,vascular access